Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection.

BACKGROUND/OBJECTIVES: As a proinflammatory cytokine, interleukin-17 (IL-17) contributes to the inflammation of many autoimmune diseases. We examined IL-17 levels in serum and tissues from patients with chronic hepatitis B virus infection (HBV), and especially evaluated the role of IL-17 in the pathogenesis and progression of liver fibrosis. MATERIALS AND METHODS: Whole venous blood was obtained from four patient groups: chronic hepatitis B (CHB, n = 47), liver cirrhosis (LC, n = 49), primary hepatocellular carcinoma (PHC, n = 44), chronic liver failure (CLF, n = 33), and a normal control group (n = 20). HBsAg was positive in all patients. Liver biopsy samples were acquired from asymptomatic HBsAg carriers (ASC, n = 35), CHB (n = 57), and LC (n = 31) patients. We performed ELISA to measure IL-17 levels in serum samples, and used reverse RT-PCR to measure IL-17 mRNA levels in peripheral blood mononuclear cells (PBMC). IL-17 protein expression was detected in liver biopsy tissues by immunohistochemistry. RESULTS: Compared to normal controls, serum IL-17 protein and mRNA levels were significantly higher in the four infection groups. LC patients exhibited the highest serum IL-17 and PBMC mRNA levels. No significant differences were found between the other three groups. High levels of IL-17 were also observed in tissues from CHB and LC patients, compared to ASC. IL-17 expression was mainly located in the portal area and was positively correlated with inflammation grade and fibrosis stage. CONCLUSIONS: IL-17 expression was found to be increased with increasing degrees of liver fibrosis. This suggests that IL-17 may not only induce the inflammation, but also contribute to disease progression and chronicity. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5306959258322482.

[Expression of interleukin-17 in hepatitis B related liver fibrosis].

AIM: To explore the role of interleukin-17 (IL-17) in the pathogenesis and progress of chronic hepatitis B virus (HBV) related liver diseases, especially in hepatitis B related liver fibrosis. METHODS: Whole vein blood was obtained from the patients with chronic hepatitis B (CHB) (n=36), liver cirrhosis (LC) (n=42) including child-pugh A (n=15), child-pugh B (n=12), child-pugh C (n=15), primary hepatitis carcinoma (PHC) (n=34), chronic severe hepatitis (n=30) and normal control (n=20).The level of serum IL-17 and the expression of IL-17 mRNA in peripheral blood mononuclear cell (PBMC) were analysed by ELISA and RT-PCR respectively. Serum IL-17 and liver fibrosis index (C-IV, LN, HA) concentration of LC classified by child-pugh scores were detected by ELISA. RESULTS: The level of serum IL-17 and the expression of IL-17 mRNA in PBMC in four HBV infectious groups were higher than that in control group ( P<0.01). The level of serum IL-17 and the expression of IL-17 mRNA in PBMC in LC group was higher than that in other groups ( P<0.01). The level of serum IL-17 and liver fibrosis index in child-pugh C group in LC patients were higher than that in Child-pugh B group and that in child-pugh B group were higher than that in child-pugh A group (P<0.01). The level of serum IL-17 in LC group positively correlated to child-pugh score and liver fibrosis index (C-IV, LN, HA) (r=0.582, 0.568, 0.682, 0.764, P<0.01). CONCLUSION: IL-17 is obviously increased in HBV related liver diseases, especially in hepatitis B related liver cirrhosis, indicating that IL-17 may play a part in the development of HBV related liver diseases, especially the pathophysiology of hepatitis B related liver fibrosis.